Form PT	D-1449 U.S.	DEPARTMENT	OF COMMERCE	ATTY. DOCKET NO.	s	ERIAL NO.	
OFFICE PATENT AND TRADEMARK		ADEMARK	2836-B 09/154,9 0		4997 E		
hiron	NAATION DIOOLO		TATION!	APPLICANT			
INFOF	RMATION DISCLO	SURE CI	TATION	Brasel et al.			FEB 0 7 2000
				FILING DATE	. G	ROUP	
	(Use several sheets	if necessar	y)	September 17, 19	998	10	A SEL
		بغ	U.S. PATEN	NT DOCUMENTS			CADEN
EXAMINER	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
N	4,745,099	05/17/88	Akamatsu e	et al.			
	5,013,824	05/07/91	Abrams et a	al.			
	5,057,420	10/15/91	Massey, Jos	seph M.			
	5,061,620	10/29/91	Tsukamoto	et al.			
	5,114,710	05/19/92	Takaku et a	1.			
	5,116,964	5/26/92	Capon et al	Capon et al.			
	5,185,438	02/09/93	Lemischka,	Ihor R.			
	5,192,553	03/9/93	Boyse et al.		_		
	5,199,942	04/6/93	Gillis, Steve	en			
W	5,270,458	12/14/93	Lemischka,	Ihor R.			
		F	OREIGN PAT	ENT DOCUMENTS			
W	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	WO 92/18615	10/29/92	PCT				
	WO 93/08268	04/29/93	PCT				
	2,163,105	05/18/94	CA	2			
2	0 627 487 A2	05/19/94	EP		-		
	OTHER DO	CUMENTS	(Including Au	thor, Title, Date, Pertiner	nt Pages, l	Etc.)	
	Stanley, E. R. et Growth Factor,"	-		elear Phagocyte Line 9, 1983.	age-Spe	cific Hemo _l	poietic
	Y. Yarden and A 57:443-478, 198		'Growth Fact	tor Receptor Tyrosine	Kinase:	s," Ann. Re	v. Biochem.
EXAMINER	Grange v	1.4/00		DATE CONSIDERED			
*EXAMINER:			or not citation i	is in conformance with MF	PEP 609; [Oraw line thro	ugh citation if
not in conf	formance and not consid	ered. Include	e copy of this fo	orm with next communicat	ion to app	licant.	

Form PTO-1449 U.S. DEPARTMENT OF COM		OF COMMERCE	ATTY, DOCKET NO.		SERIAL NO.				
PATENT AND TRADE OFFICE		ADEMARK	2836-B		09/15	54.9 9 7	Ē		
INEC		ATION DISCLO	SURE CI	ΓΔΤΙΩΝ	APPLICANT			<u>.</u>	
INFC	ZMIVIZ	ATION DISCLO	SOME OF	IAHON	Brasel et al.		D	FEB 0 7	2000
					FILING DATE		GROUP (4
	(U	se several sheets i	f necessary	·) -	September 17, 19	98	18	RADE	MAET
			<u> </u>	U.S. PATEN	IT DOCUMENTS			- VALIS	
EXAMINER		DOCUMENT NUMBER	DATE		NAME	CLAS	S SUBCLASS	FILING I	
N		4,745,099	05/17/88	Akamatsu e	t al.				
		5,013,824	05/07/91	Abrams et a	1.				
		5,057,420	10/15/91	Massey, Jos	eph M.				
		5,061,620	10/29/91	Tsukamoto	et al.				
		5,114,710	05/19/92	Takaku et al	l.	-			
0 /0	8	5,116,964	5/26/92	Capon et al.		_			_
		5,185,438	02/09/93	Lemischka,	Ihor R.	_			-
		5,192,553	03/9/93	Boyse et al.		_			
		5,199,942	04/6/93	Gillis, Steve	en				
m		5,270,458	12/14/93	Lemischka,	Ihor R.				
	77		F	OREIGN PAT	ENT DOCUMENTS	35.91.1			
.IV		DOCUMENT NUMBER	DATE		COUNTRY	CLAS	S SUBCLASS	TRANSL YES	ATION NO
1	1	WO 92/18615,	10/29/92	PCT		ļ			
	s.e.	WO 93/08268 -	04/29/93	PCT		_			_
1	, or	2,163,105	05/18/94	CA					_
9	IJ	0 627 487 A2 *	05/19/94	EP		~			
	. [OTHER DO	CUMENTS	(Including Aut	thor, Title, Date, Pertinen	t Pages	. Etc.)		
w	J		al., "CSF-	l-A Mononuc	clear Phagocyte Line			poietic	
W	Y. Yarden and A. Ullrich, "Growth Factor Receptor Tyrosine Kinases," Ann. Rev. Biochem. 57:443-478, 1988.						em.		
EXAMINE	R		1 ./ .		DATE CONSIDERED				
	Gruger V14/00 Granger 7/31/00)								
			-		s in conformance with MF			ugh citation	on if
not in c	<u>onioin</u>	iance and not consid	erea. Include	copy of this to	rm with next communicat	on to a	ppiicant.		

Form P	TO-1	449 v.s.	DEPARTMENT (OF COMMERCE	ATTY. DOCKET NO.		SERIAL NO.	
OFFICE PATENT AND TRADEMARK		NDEMARK	2836-B		09/15	4003 E		
							<u></u>	
INFORMATION DISCLOSURE CITATION			TATION	APPLICANT Description		g	FEB 0 7 2000	
					Brasel et al.		GROUP	
	(11)	se several sheets i	f n <i>ece</i> ssars	,)	September 17, 19	202	•	AADEMARKS
	(0.	se severai sneets i	, necessur y		IT DOCUMENTS	70	10	
EXAMINER		DOCUMENT NUMBER	DATE	U.S. PATEN	NAME	CLAS	S SUBCLASS	FILING DATE
Ne		5,283,354	02/01/94	Lemischka,	Ihor R.	_		IF APPROPRIATE
		5,326,558	07/05/94	Turner et al	•			
	,— <u>(</u>	5,367,057	11/22/94	Lemischka,	Ihor R.			
		5,397,706	03/14/95	Correa et al	•			
		5,399,493	03/21/95	Emerson et	al.			
		5,437,994	08/01/95	Emerson et al.				
		5,453,357	09/26/95	Hogan, Brigid L. M.		-		
		5,459,069	10/17/95	Palsson et al.		-		
		5,525,708	06/11/96	Nocka et al.				
		5,548,065	08/20/96	Lemischka, Ihor R.		_		_
		5,554,512	09/10/96	Lyman et al		<		
			F	OREIGN PAT	ENT DOCUMENTS			
		DOCUMENT NUMBER	DATE		COUNTRY	CLAS	S SUBCLASS	TRANSLATION YES NO
	,	WO 94/26891	11/24/94	PCT		< <u></u>		
	-	WO 94/28391 -	12/08/94	PCT		<u> </u>		
M	•	WO 95/00554 1	01/05/95	PCT		_		
				<u> </u>	thor, Title, Date, Pertine	-		
W	J. G. Flanagan and P. Leder, "The kit Ligand: A Cell Surface Molecule Altered in Steel Mutant Fibroblasts," Cell 63:185-194, 1990.							
N	1/	D. Cadena and C	G. Gill, "Re	ceptor tyrosi	ne kinases," FASEB	6:2332	-2337, 1992.	
EXAMINE	R				DATE CONSIDERED		, ,	
	GA	more	2/14/08	·	PHILLIP Grave	ner	7/31/00	
					s in conformance with Mi	PEP 609	; Draw line thro	ugh citation if

Form P	ГО-1	449 U.S.	DEPARTMENT (OF COMMERCE	ATTY. DOCKET NO.	St	RIAL NO.	
PATENT AND TRADEMARK OFFICE		DEMARK	2836-B		09/15	54,903		
OT TOE								
INFO	RMA	ATION DISCLO	SURE CI	TATION	APPLICANT			
					Brasel et al.			
					FILING DATE	G	ROUP	
	(Us	se several sheets <u>i</u>	f necessary	·)	September 17, 19	98	16	544
				U.S. PATEN	IT DOCUMENTS			
EXAMINER		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
M		5,843,423	12/01/98	Lyman et al	•		DE 10	
W		5,627,025	05/06/97	Steinman et	al.	-/0	7 7000	. H
N		5,635,388	06/03/97	Bennett et a	1.	1 1	(A)	
				· · · · · · · · · · · · · · · · · · ·		K	OR THADEM	9
						h j		
				Ц	-		V *	
				2.27.20				
			F	OREIGN PAT	ENT DOCUMENTS			
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
M		WO 93/20186	10/14/93	PCT				
W	/	0 563 485 A1	03/30/92	EP		_		
N	/	WO 96/00779	01/11/96	PCT				
		OTHER DO	CUMENTS	(Including Au	thor, Title, Date, Pertiner	nt Pages, E	Etc.)	
w	/	Matthews, W. et	al., "A Red	ceptor Tyrosi	ine Kinase Specific to Cell 65:1143-1152, 1	Hemate		em and
W	,	Lyman, S. D. et tyrosine kinase g			the protein encoded 22, 1993.	by the fl	t3 (flk2) re	ceptor-like
W	/	Rosnet, O. et al., Kinase Gene," G	"Isolation Genomics 9:	and Chromo 380-385, 199	somal Localization of 91.	of a Nove	l FMS-like	Tyrosine
EXAMINE	_	1 mgs	414	i	DATE CONSIDERED	un e	7/3	100
					s in conformance with MF			ugh citation if
not in co	onform	nance and not consid	ered. Include	e copy of this fo	rm with next communicat	ion to app	icant.	

Form F	PTO-1	449 U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.			
		PATENT AND TRADEMARK	2836-B	09/154,903			
OFFICE							
INIC		ATION DISCLOSURE CITATION	APPLICANT				
ווארי		ATION DISCLOSURE CITATION	Brasel et al.				
			FILING DATE	GROUP			
		(Supplemental Sheet)	September 17, 1998	1644			
		OTHER DOCUMENTS (Including Aut					
Val		Lyman, Stewart D. et al., "Molecular Cle					
VP	45	Receptor: A Proliferative Factor for Print 1993.					
FEB 0 7	2000	Maroc, N. et al., "Biochemical character	ization and analysis of the	transforming potential of			
LED O		the FLT3/FLK2 receptor tyrosine kinase	e," Oncogene 8:909-918, 19	93.			
		<i>f</i>					
RADE	AEK	Birg, F. et al., "Expression of the FMS/K					
		the Myeloid and Lymphoid Lineages," E	$8lood\ 80\ (10):2584-2593,\ 1$	992.			
•				I FILO (ELO D			
		Dosil, M. et al, "Mitogenic Signalling ar	<u> </u>	——————————————————————————————————————			
		Tyrosine Kinase in Fibroblasts and Inter	rieukin 3-Dependent Hemat	opoletic Cells, <i>Mol. Ana</i>			
		Cell. Biol. 13(10):6572-6585 1993.	V2 managartan tumpaina kinas	a magulatag grayyth of			
		Hannum, C. et al., "Ligand for FLT3/FL haematopoietic stem cells and is encoded	•				
		naematopoietic stem cens and is encoded	u by variant KNAS, <i>ivatur</i>	e 500.045-040, 1554.			
		Broxmeyer, H. E. et al., "Commentary:	A Rapid Proliferation Assa	v for Unknown Co-			
		Stimulating Factors in Cord Blood Plasm	na Possibly Involved in En	hancement of In Vitro			
		Expansion and Replating Capacity of Hu					
		Cells 20:492-497, 1994.					
i		de Vries, P. et al., "The Effect of the FL"	T3 Ligand On Purified Mun	rine Pluripotent			
		Hematopoietic Stem Cells," J. of Cell. B	•				
		Rossner, M. T. et al., "Fmş-like Tyrosine	e Kinase 3 Catalytic Doma	in Can Transduce a			
		Proliferative Signal in FDC-P1 Cells Th		o the Signal Delivered by			
		c-Fms ¹ ," Cell Growth & Differentiation		· · · · · · · · · · · · · · · · · · ·			
		Small, D. et al., "STK-1, the human hon					
	/	CD34 ⁺ human bone marrow cells and is		n of early progenitor/stem			
		cells," Proc. Natl. Acad. Sci. USA 91:45		D. I. C.I. ELLY OFFITE			
		Zeigler, F. C. et al., "Cellular and Molec					
	✓ 3 Receptor Tyrosine Kinase in Hematopoietic Stem Cells," Blood 84(8):2422-2430, 1994.						
		do Veigo Dot of "The Dole of ELT2 Li	igand in Early Muring Ham	estanciesis " Pland 84(10)			
		de Vries, P. et al., "The Role of FLT3 Li	igand in Earry Murine riem	atopolesis, biood 04(10)			
	Suppl. 1:279a, abstract #1100, 1994.						
	de Vries, P. et al., "The Effects of Soluble FLT3 Ligand On Murine Pluripotent						
	Hematopoietic Stem Cells," Experimental Hematology 22(8):724, abstract #174, 1994.						
	Inclinatopolotic Stelli Cells, Experimental Hematology 22(0): 12-1, austraet 11 11 1, 1991.						
		Stewart, F. M. et al., "Post-5-Fluorourac	il Human Marrow: Stem C	Cell Characteristics and			
1/h	Renewal Properties After Autologous Marrow Transplantation," Blood 81(9):2283-2289,						
		1993.					
EXAMINE	R		DATE CONSIDERED				
	GAMMER 2/14/00 CAMMER 7/31/00						
		tial if citation considered, whether or not citation is	s in conformance with MPEP 609	e; Draw line through citation if			

	Form P	ΓO-1	449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.		
				PATENT AND TRADEMARK	2836-B	09/154,903		
	OFFICE							
	· INEC		A TIONI	DISCLOSURE CITATION	APPLICANT			
	IINFC	'MIVIA	AHON	DISCLUSURE CHATION	Brasel et al.			
					FILING DATE	GROUP		
			(Sur	plemental Sheet)	September 17, 1998	1644		
	910	E	<u> </u>		* · · · · · · · · · · · · · · · · · · ·			
	<u> </u>	<u> </u>	}	OTHER DOCUMENTS (Including Aut				
?	FEB 0 7 2)UU _	7 1	ard, H. et al., "Generation of Imm	▼			
ļ	N	4 2	7 8	topoietic Progenitor Cells of the B	one Marrow and Peripheral	Blood, Cancer Res.		
Ç	P.			99-1104, 1995. erjee, M. et al., "Idiotypic antibody	immunotherany of cancer	" Cancar Immunol		
	RADEMAR			notherap. 38:75-82. 1994.	minumomerapy of cancer,	Cancer Immunoi.		
	M		IIIIIIIII	nomerup. 50.75-02. 1754.				
		Í	Boon	T., "Toward a Genetic Analysis o	of Tumor Rejection Antigen	s." Adv. Cancer Res.		
	ر ۵۸			7-211, 1992.	i rumor regoveron rumgen	2, 22000		
	100	,		,				
			McBr	ide, G., "New Molecule Under Stu	ıdy: Flt3 Ligand May Mob	ilize Dendritic Cells," J.		
	12		Nat'l	Cancer Inst. 89(17):1257, 1997.				
	,							
				dran, B. et al., "Developmental Par				
	Ne !			type, and Localization of Dendriti	c Cell Subsets in FLT3 Lig	and-Treated Mice," J.		
	100		ļ	nol. 159(5):2222-2231, 1997.	d C di CE	11 A (* T) 1 . (* -		
	$ \mathcal{M} $			n, M. et al., "FLT3 Ligand Induces		nally Active Dendritic		
	10	•	Cells :	in Mice," <i>Cell. Immunol. 179</i> (2):1	/4-184, 199/.			
			Chen	K. et al., "Antitumor Activity and	Immunotheraneutic Proper	ties of Flt3-Ligand in a		
	1//			e Breast Cancer Model," Cancer I	-			
			TVICITI	Dioust Carroot Wiodot, Carroot I	(10).2311 2010, 233			
		i	Strobl	, H. et al., "flt3 Ligand in Coopera	ation with Transforming Gre	owth Factor-β1		
	0.			tiates In Vitro Development of Lar	_	•		
				Pendritic Cell Cluster Formation U	_ , _			
	, ,		1434,	1997.				
	10/	· .		T. et al., "Chronic Expression of N	,			
	14			ating White Blood Cell Levels and		ates Associated With		
	4			ic Fibrosis," <i>Blood 90(1)</i> :76-84, 19				
	M	,	, ,	, D. et al., "Flt3 ligand induces tui		or immune responses in		
			vivo,''	Nature Med. 3(6):625-631, 1997.				
		-	Course	lers, D. et al., "Dendritic Cell Deve	alanment in Cultura from T	hymic Precursor Calls in		
		4		osence of Granulocyte/Macrophage	^	*		
				185-2196, 1996.	c colony-summaring racto	1, J. Exp. Med.		
		···•			ase in the Numbers of Func	tionally Mature Dendritic		
	[/ h	Maraskovsky, E. et al., "Dramatic Increase in the Numbers of Functionally Mature Dendritic Cells in Flt3 Ligand-treated Mice: Multiple Dendritic Cell Subpopulations Identified," J.						
			Exp. Med. 184:1953-1962, 1996.					
	^-		E. Spr	echer and Y. Becker, "Role of Lar	ngerhans cells and other der	ndritic cells in viral		
	diseases," Arch. Virol. 132:1-28, 1993.							
				······································				
	EXAMINEF	3			DATE CONSIDERED			
	Compa Virlos Gonner Holos							
				ation considered, whether or not citation i				
	not in cor	itorma	ince and	I not considered. Include copy of this form	m with next communication to ap	piicant.		

Form PTO	-1449	U.S. DEPARTMENT OF COMMERCE	ATTY, DOCKET NO.	SERIAL NO.		
		PATENT AND TRADEMARK	2836-B	09/154,903		
OFFICE						
INFORM	MATION D	ISCLOSURE CITATION	APPLICANT			
	VIATION D	NOCEOSO THE OTTATION	Brasel et al.			
			FILING DATE	GROUP		
	(Suppl	emental Sheet)	September 17, 1998	1644		
<u> </u>		THER DOCUMENTS (Including Aut				
10		yer, H. et al., "Flt3 ligand stimul				
	-	genitor cells," Exp. Hematol. 23		,		
₹ 🍪 ֱ	124	, 1	. /			
	A. Porga	dor and E. Gilboa, "Bone Marre	ow-generated Dendritic Cel	ls Pulsed with a Class I-		
B M PG		d Peptide are Potent Inducers of				
Con Co	£ 260, 199	•				
COPPE	Hudak, S	S. et al., "FLT3/FLK2 Ligand Pr	romotes The Growth Of Mu	rine Stem Cells And The		
		on Of Colony-Forming Cells Ar				
0 1	85(10):2	747-2755, 1995.				
		M. et al., "FLK-2/FLT-3 Ligar				
	/ Progenit	ors Isolated From Human Fetal	Liver," Blood 85(4):963-97	72, 1995.		
	1	n, R., "The Dendritic Cell Syster	m and Its Role in Immunogo	enicity," Annu. Rev.		
	Immuno	<i>l.</i> 9:271-296, 1991.				
	1					
		ia, S. et al., "Primary proliferati	<i>1</i>	ponses to HIV induced in		
	vitro by	human dendritic cells," Immunc	ology 74:399-406, 1991.			
			T	1 T. C. 11-		
		, P. et al., "Dendritic Cells Effic	•			
	224, 199	in Blood, Including Clonable Ai	nugen-Reactive Plecuisors,	Immunology 70.217-		
		. et al., "Dendritic Cells Pulsed	With Protein Antigens In V	Vitro Can Prime Antigen-		
	•	, MHC-Restricted T Cells In Sit				
	Specific,	, which confided a constant	.u, J. 12.051 0	10, 1550.		
	Buidoso	, R. et al., "Afferent Lymph Der	ndritic Cells: A Model For	Antigen Capture And		
		tion In Vivo," Intern. Rev. Immu				
		••••••••••••••••••••••••••••••••••••••				
	Jaffe, R.	, "Review Of Human Dendritic	Cells: Isolation And Cultu	re From Precursors,"		
		c Pathology 13:821-837, 1993.				
	Bermste	in, I. et al., "Isolation Of Humar	n Hematopoietic Stem Cells	s," Blood Cells 20:15-24,		
	1994.					
			·- ·- ·- ·- ·- ·- ·- ·- ·- ·- ·- ·- ·- ·	· · · · · · · · · · · · · · · · · · ·		
		I. et al., "Identification Of Dend				
		CD34 ⁺ Bone Marrow Progenitor				
	Pure Dendritic Cell Colonies In The Presence Of Granulocyte/Macrophage Colony-					
		ing Factor And Tumor Necrosis				
7		et al., "Dendritic Cell Progenit				
1		e-Guerin Organisms, And Sensit	tize Mice To Mycobacterial	Antigens In Vivo," J.		
EVANINED	Exp. Me	d. 178:479-488, 1993.	DATE CONSIDERED			
EXAMINER	\wedge		DATE CONSIDERED			
	GAMBA V/14/00 GAMBOR Flacos					
		n considered, whether or not citation i				
HOL IN CONTOR	mance and no	ot considered. Include copy of this form	n with next communication to ap	Pilicarit.		

Form P	TO-1	449 U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.		
OFFICE	PATENT AND TRADEMARK		2836-B	09/154,903		
INFO	ORM/	ATION DISCLOSURE CITATION	APPLICANT Brasel et al.	<u></u>		
			FILING DATE	GROUP		
		(Supplemental Sheet)	September 17, 1998	1644		
		OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinent Pages	s, Etc.)		
DIP		Papayannopoulo et al., "In Vivo Effects Hematopoietic Progenitors in Primates a Granulocyte Colony-Stimulating Factor	and Potent Synergistic Enha	incement With		
a. M		Lotem, J. and Sachs, L., "Control of In Leukemia 2(12 Suppl.):24S-37S, 1988.	<i>*</i>			
RADEMAS	./	Stewart D. Lyman et al., "Cloning of the Growth Factor for Early Hematopoietic		-		
		D. Hanahan, "Transgenic Mice as Probe 1989.	es into Complex Systems,"	Science 246:1265-1275,		
	/	Romani, N. et al., "Proliferating Dendrit 180:83-93, 1994.	,	<u></u>		
		Winton, E. F. et al., "Recombinant Hum Causes a Marked CD34 ⁺ Cell Mobilization December 1996.				
		F. Sallusto and A. Lanzavecchia, "Efficient Human Dendritic Cells is Maintained by Plus Interleukin 4 and Downregulated by 1118, 1994.	y Granulocyte/Macrophage	Colony-stimulating Factor		
	1	Szabolcs, P. et al, "Expansion of Immur Progeny of Human CD34 [†] Bone Marrov Macrophage Colony-Stimulating Factor	w Precursors Cultured with	c-kit Ligand, Granulocyte-		
	/	Rosnet, O. et al., "Murine Flt3, a gene e PDGFR/CSF1R family," Oncogene 6:10		nase receptor of the		
M	S. Stengelin et al., "Isolation of cDNAs for two distinct human Fc receptors by ligand affinic cloning," <i>EMBO J. 7(4)</i> :1053-1059, 1988					
M	Debets, R. and Savelkoul, H. F. J. "Cytokine antagonists and their potential therapeutic use," <i>Immunol. Today 15(10)</i> :455-458, 1994.					
N	Small et al., "STK-1 is Expressed in a Subpopulation of Human Bone Marrow Enriched for CD34 ⁺ Progenitor/Stem Cells and in a Number of Leukemic Cell Lines," <i>Blood 80</i> , 296a; Abstract No. 1175, 1992.					
1	Reid, D. L. et al., "Interactions Of Tumor Necrosis Factor With Granulocyte-Macrophage Colony-Stimulating Factor And Other Cytokines In The Regulation Of Dendritic Cell Growth In Vitro From Early Bipotent CD34 ⁺ Progenitors In Human Bone Marrow," <i>J. of Immunol.</i> 149(8):2681-2688, 1992.					
EXAMINE	GAMMA VIMOO DATE CONSIDERED GAMMA VIMOO GAMMA TIGO					
1	*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Form PTO	-1449 U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.			
OFFICE	PATENT AND TRADEMARK	2836-B	09/154,903			
INFOR	MATION DISCLOSURE CITATION	APPLICANT				
		Brasel et al.	•			
		FILING DATE .	GROUP			
	(Supplemental Sheet)	September 17, 1998	1644			
	OTHER DOCUMENTS (Including A					
	Thomson, A. W. et al., "Microchimeris	-	rs and Transplantation			
	Tolerance," Stem Cells 13:622-639, 19	95.				
FER 0 7 2800		1 1 1 1 1 T 1 1 T 1 T 1 T 1 T 1 T 1 T 1	1 C C - 11			
	Lyman, S. D. and Jacobsen, S. E. W., "					
ار ا م	Factors With Overlapping Yet Distinct	Activities, Blood 91(4): 11	01-1134, 1998.			
RADEMARK	Dov. D. L. et al. "Elt2 ligand aumnosta t	ha differentiation of early D	call progenitors in the			
	Ray, R. J. et al., "Flt3 ligand supports t		cen progenitors in the			
	presence of IL-11 and IL-7," Manuscri	pt, reditiary 20, 1990.				
	Chklovskaia, E. et al., "Increased Produ	ection of FLT3 Ligand in Le	ukemia Patients With			
	Chemotherapy-Induced Bone Marrow	_				
	Meeting of the European Haematology	* *				
	Wodnar-Filipowicz, A. et al., "Tyrosing					
1 / 1	anemia," Manuscript, February 20, 199	-	8 1			
		,				
	Hsu, F. et al, "Antigen-Pulsed Dendriti	c Cells in the Treatment of F	Patients with B-cell			
	Lymphoma," Abstract # C1-314, Keyst					
	Drexhage, H. A., "A Defective Maturat					
	Diabetics," Abstract # C1-204, Keyston	ne Conference, Taos, NM, M	Iarch 1995.			
		11 4				
	Fisch, P. et al., "Ex Vivo Generation of					
	Peripheral Blood CD34 ⁺ Hematopoietic	_	Patients, Abstract # C1-			
	311, Keystone Conference, Taos, NM,		Dotont Adiguents for			
	Mayordomo, J. et al., "Bone Marrow-D Peptide-Based Antitumor Vaccines," A					
	March 1995.	Ustract # C1-213, Reystone	Comercies, 1 aos, 1 vivi,			
	Lenz, P. et al., "MHC Class I*/II Dend	ritic Cells Sensitize for Tran	splantation Immunity."			
	Abstract # C1-318, Keystone Conferen		-F,			
		,, - ·-·-, - · 				
	Ye, Z. et al., "Evaluation of Dendritic (Cells in Allogeneic Marrow	Grafts," Abstract # C1-			
	130, Keystone Conference, Taos, NM,		•			
Thomson, A. W. et al., "Growth of Donor-Derived Dendritic Cells From the Bone Marrov						
1 1 1	Murine Liver Allograft Recipients in Response to Granulocyte/Macrophage Colony-					
	Stimulating Factor," Abstract # C1-125					
in	Whalen, R. G. et al., "DNA-Mediated I					
Potential Involvement of Interstitial Dendritic Cells," Abstract # C1-128, Keystone						
EVANINED	Conference, Taos, NM, March 1995.	DATE CONSIDERED				
EXAMINER	GAMME V/14/00 DATE CONSIDERED GAMMED 2/2/60					
B .	Initial if citation considered, whether or not citation					
Linor in confor	mance and not considered. Include copy of this fo	mi with hext communication to ap	Piloait.			

INFORMATION DISCLOSURE CITATION APPLICANT Brasel et al. FILING DATE September 17, 1998 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Alters, S. et al., "Characterization and Gene Modification of Dendritic Cells to be Used for Antigen Presentation, Abstract # C1-302, Keystone Conference, Taos, NM, March 1995.	Form P	TO-1	449 U.S	S. DEPARTMENT OF COMMERCE	ATTY, DOCKET NO.	SERIAL NO.
Brasel et al. FILING DATE (Supplemental Sheet) OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Alters, S. et al., "Characterization and Gene Modification of Dendritic Cells to be Used for Antigen Presentation, Abstract # C1-302, Keystone Conference, Taos, NM, March 1995. FB 0 7 2000 DATE CONSIDERED CHARACTERIZATION TEXAMINER: Initial it citation considered, whether or not citation is in conformance with MPEP 809; Draw line through citation if	OFFICE			PATENT AND TRADEMARK	2836-B	09/154,903
Brasel et al. FUND DATE GROUP September 17, 1998 1644	INFORMATION DISCLOSURE CITATION				APPLICANT	<u>l</u>
September 17, 1998 OTHER DOCUMENTS (Including Author, Title, Date, Pertineur Pages, Etc.) Alters, S. et al., "Characterization and Gene Modification of Dendritic Cells to be Used for Antigen Presentation, Abstract # C1-302, Keystone Conference, Taos, NM, March 1995. FB 9 7 2000 DATE CONSIDERED CAMBER Lation considered, whether or not oitation is in gordremance with MPEP 609, Draw line through citation if	INFC	VI JIVIV	ATION DISCLO	JOHL CHATION	Brasel et al.	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Alters, S. et al., "Characterization and Gene Modification of Dendritic Cells to be Used for Antigen Presentation, Abstract # C1-302, Keystone Conference, Taos, NM, March 1995. OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Alters, S. et al., "Characterization and Gene Modification of Dendritic Cells to be Used for Antigen Presentation, Abstract # C1-302, Keystone Conference, Taos, NM, March 1995. OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Alters, S. et al., "Characterization and Gene Modification of Dendritic Cells to be Used for Antigen Presentation, Abstract # C1-302, Keystone Conference, Taos, NM, March 1995. Texaminer (Including Author) Date on State (Including Author) Date on					FILING DATE	GROUP
Alters, S. et al., "Characterization and Gene Modification of Dendritic Cells to be Used for Antigen Presentation, Abstract # C1-302, Keystone Conference, Taos, NM, March 1995. FER 0 7 2000 FER 0 7 2000 DATE CONSIDERED CONVICTOR 101/16 If citation considered, whether or not citation is in conformance with MPEP 809; Draw line through citation if			(Supplementa	l Sheet)	September 17, 1998	1644
Antigen Presentation, Abstract # C1-302, Keystone Conference, Taos, NM, March 1995. FER 9 7 2000 ADDRESS EXAMINER LAMAR VIII DATE CONSIDERED GAMAGE 1/31/2016 CAMAGE 1/31/2016 FEXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if			OTHER D	OCUMENTS (Including Au	thor, Title, Date, Pertinent Page.	s, Etc.)
EXAMINER CAMAGE VIIIO DATE CONSIDERED CAMAGE VIIIO (EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 809; Draw line through citation if	No	Ċ				
EXAMINER CA MAGE VIVIA DATE CONSIDERED CANAGE VIVIA CANAGE VIVIA SEXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if		PK	V C			·
EXAMINER CAMPLE VIDO DATE CONSIDERED CAMPLE VIDO CAMPLE VIDO TEXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if			JOE TO THE PROPERTY OF THE PRO		· 	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if	RADE	AABK			·	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if				•		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if					· · · · · · · · · · · · · · · · · · ·	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if					•	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if					· · · · · · · · · · · · · · · · · · ·	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if	EXAMINE	3		, ,	DATE CONSIDERED	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if			(my	a Willow	Gamage 2	(316of)
					is in conformance with MPEP 609	9; Draw line through citation if